Erythropoietic stimulating agents and quality of a patient's life: Individualizing anemia treatment

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 2, 2012, Pages 354-357

  Kliger, Alan S ^a   Fishbane, Steven ^b   Finkelstein, Fredric O ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DYSPNEA; ENERGY; FATIGUE; HEART INFARCTION; HUMAN; MORTALITY; PERCEPTION; PHYSICIAN; PRACTICE GUIDELINE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SELF REPORT; STROKE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ACCESS; WEAKNESS;

ANEMIA; BIOLOGICAL MARKERS; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMOGLOBINS; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY DISEASES; PATIENT SELECTION; PERCEPTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84857163463     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11961111     Document Type: Article

References (34)

1. Procrit [package insert].Horsham, PA, Janssen BiotechInc, 2011. Available at: http://www.procrit.com/sites/default/files/shared/ OBI/PI/ProcritBooklet.pdf#page=1. Accessed November 17, 2011
2. Arbor Research Collaborative for Health: DOPPS Practice Monitor. Available at: http://www.dopps.org/DPM/Default.aspx. Accessed November 17, 2011
3. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
6. Sexauer CL, Matson JR: Anemia of chronic renal failure. Ann Clin Lab Sci 11: 484-487, 1981
7. National Kidney Foundation-Dialysis Outcomes Quality Initiative: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30[Suppl 3]: S192-S240, 1997
8. USRenal Data System: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease inthe United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
9. Besarab A, Goodkin DA, Nissenson AR; Normal Hematocrit Cardiac Trial Authors: The normal hematocrit study-follow-up. N Engl J Med 358: 433-434, 2008
10. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
11. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
12. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF: Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23-33, 2010
13. Weiner DE, Miskulin DC: Anemia management in chronic kidney disease: Bursting the hemoglobin bubble. Ann Intern Med 153: 53-55, 2010
14. Collins AJ: Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl (80): 44-48, 2002
15. Weisbord SD, Kimmel PL: Health-related quality of life in the era of erythropoietin. Hemodial Int 12: 6-15, 2008
16. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS; FHN Trial Group: In-center he-modialysis six times per week versus three times per week. N Engl J Med 363: 2287-2300, 2010
17. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH: Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med 171: 1854-1856, 2011
18. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with re-combinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987
19. Bommer J, Müller-Bühl E, Ritz E, Eifert J: Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet 1: 392, 1987
20. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from re-combinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175-1178, 1986
21. Evans RW, Rader B, Manninen DL; Cooperative Multicenter EPO Clinical Trial Group: The qualityof life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263: 825-830, 1990
22. Jaber BL, Finkelstein FO, Glickman JD, Hull AR, Kraus MA, Leypoldt JK, Liu J, Gilbertson D, McCarthy J, Miller BW, Moran J, Collins AJ; FREEDOM Study Group: Scope and design of the Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements (FREEDOM) Study. Am J Kidney Dis 53: 310-320, 2009
23. Jaber BL, Lee Y, Collins AJ, Hull AR, Kraus MA, McCarthy J, Miller BW, Spry L, Finkelstein FO; FREEDOM Study Group: Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: Interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis 56: 531-539, 2010
24. US Food and Drug Administration: Guidance for Industry: Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims, 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/ucm193282. pdf. Accessed November 22, 2011
25. Centers for Medicare and Medicaid Services: Clinical Performance Measures (CPM) Project, 2011. Available at: http://www.cms.hhs.gov/cpmproject. Accessed November 17, 2011
26. Leaf DE, Goldfarb DS: Interpretation and reviewof health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 75: 15-24, 2009
27. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ: Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55: 535-548, 2010
28. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML: Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. Am J Kidney Dis 55: 519-534, 2010
29. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ: The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-analysis. Arch Intern Med 169: 1104-1112, 2009
30. Canadian Erythropoietin Study Group: Association between re-combinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
31. Muirhead N, Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, Gitlin M, Mayne TJ: Dialysis patients treated with epoetin a show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 14: 168-173, 2010
32. Green JA, Mor MK, Shields AM, Sevick MA, Palevsky PM, Fine MJ, Arnold RM, Weisbord SD: Prevalence and demographic and clinicalassociations ofhealth literacyin patients onmaintenance hemodialysis. Clin J Am Soc Nephrol 6: 1354-1360, 2011
33. Hedayati SS, Finkelstein FO: Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis 54: 741-752, 2009
34. Cukor D, Coplan J, Brown C, Friedman S, Newville H, Safier M, Spielman LA, Peterson RA, Kimmel PL: Anxiety disorders in adults treated by hemodialysis: A single-center study. Am J Kidney Dis 52: 128-136, 2008